Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Immunogenicity of IPV With or Without dmLT in Healthy Adults
NCT04232943Phase 1Completed
- Sponsor
- PATH
- Start
- Jan 2020
- Primary completion
- Feb 2021
- Modality
- Recombinant Proteins and Enzymes, Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised trial of dmLT in poliomyelitis (3 arms), sponsored by PATH. Primary endpoints: Serious Adverse Events up to 6 months, Severe Adverse Events up to 28 days and 4 more. Started Jan 2020; status: completed.
02
Drugs
dmLT
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT04232943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04232943.